Transplants, Decompensation, and the True Cost of Untreated MASH

This episode, titled 'Transplants, Decompensation, and the True Cost of Untreated MASH,' features Nadege Gunn, MD discussing the following critical question:

How do the costs associated with decompensated cirrhosis, liver transplantation, or hepatocellular carcinoma compare to the cost of treating MASH pharmacologically at an earlier stage?

Nadege Gunn examined the stark economic contrast between the cost of early pharmacologic intervention in MASH and the astronomical healthcare utilization associated with late-stage liver disease, arguing that the cost of allowing MASH to progress unchecked to the point of hepatic decompensation, liver transplantation, or hepatocellular carcinoma far exceeds the investment required to treat the disease earlier with therapies capable of reversing fibrosis and resolving MASH before those devastating endpoints are reached. She drew a parallel to the well-established preventive care model in cardiovascular disease, where managing weight, diet, cholesterol, and blood pressure is understood to prevent catastrophic and costly events like myocardial infarction and stroke, arguing that the same logic applies to MASH, where early weight management, lifestyle counseling, and liver-directed pharmacotherapy represent a far more economically sound strategy than reactive management of end-stage complications. Nadege Gunn concluded that reducing downstream healthcare utilization events such as hospitalizations, hepatic encephalopathy, and decompensation is not only clinically meaningful for patients but represents a compelling economic argument for payers, health systems, and policymakers to prioritize earlier identification and treatment of MASH in at-risk populations.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective,' Mazen Noureddin, MD, MHSc, FAASLD will share his perspective on the relationship between obesity and MASH, discussing how insulin resistance and metabolic dysfunction drive liver disease within the broader cardio-liver-renal metabolic syndrome framework, why MASH so often goes undetected in its early stages, and what prompts clinicians to start looking for MASH in at-risk patient populations.